FDA approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules, Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA) to treat gastroesophageal reflux disease (GERD) in adults and children aged 1 year and older. Esomeprazole is a proton pump inhibitor that reduces the amount of acid in the stomach.
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.
Prolonged use of proton pump inhibitors (PPIs) may disrupt the makeup of bacteria in the digestive system, potentially raising the risk of Clostridium difficile infection (CDI), according to a study published in Microbiome.
Distinguishing between gastroesophageal reflux (GER) and gastroesophageal reflux disease (GERD) in infants is critical to providing appropriate treatment and avoiding overclassifying infants with GERD that leads to overtesting and overtreatment.
Chait Maxwell, MD, Gastroenterologist with the ColumbiaDoctors Medical Group, discusses Gastroesophageal Reflux Disease (GERD), one of the most common upper GI maladies affecting people in the United States. Video provided by The Doctor's Channel.
Amneal Pharmaceuticals will start shipping its branded Esomeprazole Strontium 49.3 mg delayed-release capsules on December 18 to three major U.S. wholesalers. Its capsules contain the same active ingredient, esomeprazole, in a different salt form, as found in Nexium (esomeprazole magnesium).
Amneal Pharmaceuticals will start shipping its branded Esomeprazole Strontium 49.3 mg delayed-release capsules on December 18 to three major U.S. wholesalers. Its capsules contain the same active ingredient, esomeprazole, in a different salt form as found in Nexium (esomeprazole magnesium).
Eosinophilic esophagitis is an increasingly recognized condition in children and adults that may mimic gastroesophageal reflux but that does not respond to acid suppression. Current treatment focuses on dietary modification and topical corticosteroids. However, future studies are needed to better define this disease’s natural history and to identify effective therapies for children and adults.